{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:40:29Z","timestamp":1771562429358,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.gore.2023.101296","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:19:31Z","timestamp":1697771971000},"page":"101296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4009-4490","authenticated-orcid":false,"given":"Brandon I.","family":"Ing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Kuhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Glassman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynae A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2023.101296_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-021-00301-z","article-title":"Immunotherapy in endometrial cancer: rationale, practice and perspectives","volume":"9","author":"Cao","year":"2021","journal-title":"Biomark Res."},{"key":"10.1016\/j.gore.2023.101296_b0010","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.3390\/jcm11174993","article-title":"Ocular Inflammation Induced by Immune Checkpoint Inhibitors","author":"Chaudot","year":"2022","journal-title":"J. Clin. Med."},{"issue":"18","key":"10.1016\/j.gore.2023.101296_b0015","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.3390\/cancers13184659","article-title":"PD-L1 Expression is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (basel)."},{"issue":"21","key":"10.1016\/j.gore.2023.101296_b0020","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.21037\/atm-22-721","article-title":"Clinical features and long-term treatment outcome of posterior scleritis","volume":"10","author":"Lee","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.gore.2023.101296_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gore.2023.101296_b0030","article-title":"Pembrolizumab-Induced Nodular Posterior Scleritis","author":"Mcnelly","year":"2023","journal-title":"Sage J."},{"key":"10.1016\/j.gore.2023.101296_b0035","unstructured":"Mechanism of Action: Keytruda (pembrolizumab: PD-1 Receptor Blockade). Merck & Co, 2023. Available at https:\/\/www.keytrudahcp.com\/resources\/mechanism-of-action\/. Accessed June 8, 2023."},{"issue":"7","key":"10.1016\/j.gore.2023.101296_b0040","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in Patients with Microsatellite Instability- High Advanced Endometrial Cancer: Results from KeyNote-158 Study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2023.101296_b0045","unstructured":"Selected Adverse Reactions. Advanced MSI-H\/dMMR Cancers. Merck & Co, 2023. Available at https:\/\/www.keytrudahcp.com\/safety\/adverse-reactions\/msi-h-dmmr\/. Accessed on June 8, 2023."},{"issue":"36","key":"10.1016\/j.gore.2023.101296_b0050","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2023.101296_b0055","unstructured":"Severe and Fatal Immune-Mediated Adverse Reactions. Merck & Co, 2023. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125514s110lbl.pdf. Accessed on June 8, 2023."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:58:36Z","timestamp":1762480716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923003132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":11,"alternative-id":["S2352578923003132"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101296","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101296"}}